JMP Securities analyst Gobind Singh reiterated a Buy rating on Protagonist Therapeutics (NASDAQ:PTGX) on Friday, setting a price target of $55, which is approximately 19.23% above the present share price of $46.13.
Singh expects Protagonist Therapeutics to post earnings per share (EPS) of -$0.69 for the third quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Protagonist Therapeutics, with an average price target of $62.
The analysts price targets range from a high of $93 to a low of $50.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $2.27 million and a net profit of -$30.88 million. The company's market cap is $2.19 billion.
According to TipRanks.com, JMP Securities analyst Gobind Singh is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -7.0% and a 40.00% success rate.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.